載入...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Chinês |
| 出版: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| 叢編: | Chinese Journal of Lung Cancer |
| 主題: | |
| 在線閱讀: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|